A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis
This research is testing a new drug called ARGX-119 for people living with Amyotrophic Lateral Sclerosis (ALS), often known as Motor Neurone Disease. This is an early phase study (Phase 2a), which means it's one of the first times this drug is being tested in a larger group of people with ALS. The main goals are to check if the drug is safe, how well people tolerate it, and if it might have any positive effects on the condition. The study is 'double-blinded,' meaning neither you nor your study doctor will know if you are receiving the active drug or a 'placebo' (a dummy treatment with no active medicine). This helps ensure fair and accurate results. There's also an 'active-treatment extension' part, where participants might continue to receive the active drug after the main study period. Researchers will look for any side effects, and how the body handles the medicine.
At a glance
What is this study about?
This study is particularly important because it's exploring a new potential treatment, ARGX-119, for people with Amyotrophic Lateral Sclerosis (ALS). ALS is a serious condition that affects nerve cells in the brain and spinal cord, leading to muscle weakness and problems with movement. Currently, there isn't a cure for ALS, so finding new ways to manage the condition and improve quality of life is very important.
The study aims to understand several key things about ARGX-119. Firstly, it focuses on safety – researchers want to know if the medicine causes any unwanted side effects and how well people can cope with them. Secondly, they're looking at 'tolerability,' which means how easily people can take the medicine without too much discomfort. Thirdly, they will explore if the medicine shows any early signs of helping with the symptoms of ALS.
The trial is designed as a 'double-blinded' study, which is a common and important way to conduct medical research. This means that during the study, neither you nor your doctors will know whether you are receiving the active medicine (ARGX-119) or a 'placebo' (a treatment that looks exactly like the active medicine but contains no active drug). This method helps to ensure that the results are as fair and unbiased as possible. After a certain period, there's also an 'active-treatment extension,' where participants might get the opportunity to continue receiving the active drug.
Key takeaways
- This study is testing a new medicine (ARGX-119) for Amyotrophic Lateral Sclerosis (ALS).
- It's an early-stage study focusing on safety, how well people tolerate the medicine, and potential benefits.
- You might receive the active medicine or a placebo (dummy medicine) during the study.
- Regular health checks, blood tests, and heart tests will be part of your participation.
- You can stop taking part in the study whenever you wish, without affecting your care.
Who may be eligible?
To join this study, you must be 18 years old or older. The study is open to both men and women.
There will be other specific rules about who can take part, which will depend on your health and your current medical treatments. These detailed rules are important to make sure the study is safe for you and that the results are clear.
It's very important to discuss your full medical history with the study team. They will carefully check if this study is suitable for you based on all the criteria.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Amyotrophic Lateral Sclerosis (ALS)?
- Are you able to attend regular appointments at a study clinic?
- Are you willing to potentially receive either the new drug or a placebo?
- Are you comfortable with blood tests and other routine checks?
What does participation involve?
If you decide to take part, you will have regular visits to the study clinic. During these visits, the study team will carefully monitor your health. This will include keeping an eye on any side effects, carrying out blood and urine tests, and doing heart checks like ECGs. Your vital signs (such as blood pressure and heart rate) will also be checked regularly.
You will receive either the study medicine, ARGX-119, or a placebo (a dummy medicine) through an infusion, which is given directly into a vein. The duration of the study will involve initial treatment and then a potential extension period. Throughout your participation, researchers will also measure how the drug moves through your body and look for any immune reactions your body might have to the medicine. The total length of your involvement will be clearly explained by the study team.
Potential risks and benefits
Locations (5)
- —UnverifiedDenmark
- —UnverifiedFrance
- —UnverifiedNetherlands
- —UnverifiedSweden
- —UnverifiedBelgium
Common questions
What is ALS?
ALS stands for Amyotrophic Lateral Sclerosis, also known as Motor Neurone Disease. It's a condition that affects nerve cells, leading to muscle weakness over time.
What does 'double-blinded' mean?
It means neither you nor your study doctor will know if you are receiving the active medicine or a placebo (a dummy treatment). This helps make the study fair and the results accurate.
Will I definitely get the new medicine?
In the main part of the study, you will either receive the new medicine (ARGX-119) or a placebo. There is an 'extension' part where you might have the chance to receive the active medicine.
What is the study trying to find out?
The study wants to see if ARGX-119 is safe, if people can tolerate it well, and if it shows any early signs of helping with ALS. They will also look at how your body handles the medicine.
Can I stop participating if I want to?
Yes, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.